MLXIPL and fatty liver disease: Insulin resistance further exacerbates hepatic steatosis, as insulin’s ability to suppress adipose tissue lipolysis diminishes while simultaneously activating de novo lipogenesis pathways through transcription factors like SREBP-1c and carbohydrate-responsive element binding protein (ChREBP) [20].